Demand for weight-loss and diabetes drugs seen global surge, CEO says move will come once patents begin to expire next year ...

Combination therapy with cagrilintide and semaglutide vs cagrilintide alone, semaglutide alone, and placebo is superior for improving weight loss results.

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.